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Original articleMice lacking neutral amino acid transporter
B0AT1 (Slc6a19) have elevated levels of FGF21
and GLP-1 and improved glycaemic controlYang Jiang 1, Adam J. Rose 2, Tjeerd P. Sijmonsma 2, Angelika Bröer 1, Anja Pfenninger 3, Stephan Herzig 2,
Dieter Schmoll 3, Stefan Bröer 1,*ABSTRACT
Objective: Type 2 diabetes arises from insulin resistance of peripheral tissues followed by dysfunction of b-cells in the pancreas due to
metabolic stress. Both depletion and supplementation of neutral amino acids have been discussed as strategies to improve insulin sensitivity.
Here we characterise mice lacking the intestinal and renal neutral amino acid transporter B0AT1 (Slc6a19) as a model to study the consequences
of selective depletion of neutral amino acids.
Methods: Metabolic tests, analysis of metabolite levels and signalling pathways were used to characterise mice lacking the intestinal and renal
neutral amino acid transporter B0AT1 (Slc6a19).
Results: Reduced uptake of neutral amino acids in the intestine and loss of neutral amino acids in the urine causes an overload of amino acids in
the lumen of the intestine and reduced systemic amino acid availability. As a result, higher levels of glucagon-like peptide 1 (GLP-1) are produced
by the intestine after a meal, while the liver releases the starvation hormone ﬁbroblast growth factor 21 (FGF21). The combination of these
hormones generates a metabolic phenotype that is characterised by efﬁcient removal of glucose, particularly by the heart, reduced adipose tissue
mass, browning of subcutaneous white adipose tissue, enhanced production of ketone bodies and reduced hepatic glucose output.
Conclusions: Reduced neutral amino acid availability improves glycaemic control. The epithelial neutral amino acid transporter B0AT1 could be a
suitable target to treat type 2 diabetes.
Crown Copyright  2015 Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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In the development of insulin resistance, the role of protein nutrition in
general, and of neutral amino acids in particular, is controversial. When
provided in excess, amino acids, like fat and carbohydrate, can cause
insulin resistance [1e3]. This is thought to involve the amino acid
sensing mTORC1 complex [4,5]. Activation of mTORC1 and its
downstream protein kinase p70S6K are known to phosphorylate in-
sulin receptor substrate, which in turn will reduce the response to
insulin [1]. Cellular, animal and human intervention studies, however,
have yielded controversial results. Some studies reported improved
insulin sensitivity after supplementation of leucine and other branched-
chain amino acids [6e8], while other studies reported improved insulin
sensitivity when neutral amino acids were curtailed [9,10]. A
comprehensive feeding study in mice using different ratios of the three
macronutrients pointed to a correlation between high protein intake,1Research School of Biology, The Australian National University, Canberra, ACT 0200
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studies have consistently shown that slight elevations of plasma
neutral amino acids are good predictors of future diabetes [12,13].
Thus it has been proposed that elevated intake of these amino acids
causes insulin resistance through a variety of mechanisms including
mTOR activation and generation of short-chain fatty acids [14]. While
abundance of amino acids is sensed through the mTOR pathway,
depletion of amino acids is sensed through the GCN2/ATF4 pathway
[15]. This pathway is activated by uncharged tRNA’s, resulting in a
general shutdown of protein translation through phosphorylation of
protein translation initiation factors. At the same time selected tran-
scripts are activated through an amino acid response element. Among
the transcripts that are activated through this response are amino acid
transporters in the pancreas [16] and FGF21 in the liver [17,18]. FGF21
is a metabolic hormone that induces a metabolic program adapting the
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glucose uptake into adipocytes independent of insulin [19], FGF21
generates a complex pattern of effects such as reduced serum
glucose, triglycerides, fatty acids and insulin, while ketone body pro-
duction is increased [19,20]. It is thought that most of the FGF21
metabolic effects are generated through its action on adipose tissue
[21], where it also increases adiponectin release [22]. Amino acids also
act as secretagogues of insulin secretion in b-cells or indirectly
through the secretion of GLP-1 and GIP by L- and K-cells in the in-
testine [23,24]. Calorie-reduced high protein diets are frequently used
as a tool to manage weight problems [25]. Low protein diets, by
contrast, have been proposed to cause hyperphagic behaviour
resulting in obesity [26]. Related to this amino acids are sensed by the
central nervous system and play an important role in the generation of
satiety [27].
Due to the multitude of effects that amino acids have in the regulation
of metabolism, pharmacological targets have so far failed to emerge.
While acute use of mTOR inhibitors indeed reduces insulin resistance,
chronic use of mTOR inhibitors, given for instance as immunosup-
pressants after transplantation, can induce insulin resistance and
cause diabetes [28]. Plasma amino acid levels are regulated through
transport, metabolic processes and protein turnover. Liver, muscle,
intestine, brain and kidney are organs with signiﬁcant amino acid
metabolism, while muscle is the main organ for storage [29]. Amino
acid intake is mediated by group-speciﬁc amino acid transporters in
the intestine, while the kidney ﬁlters and reabsorbs amino acids [30].
The amino acid transporter B0AT1 (Slc6a19) is the major epithelial
transporter for neutral amino acids in the intestine and kidney [31]. As
a result lack of Slc6a19 causes a selective deﬁciency of neutral amino
acids, which can be used to address the role of neutral amino acids in
metabolic regulation [32]. The deﬁciency is incomplete because amino
acids are also absorbed as di- and tri-peptides via peptide transporter
PepT1 in the intestine [33]. Inactivating mutations in B0AT1 (SLC6A19)
in humans are known to cause Hartnup disorder, a largely benign
disorder, which is characterised by large amounts of neutral amino
acids spilling over into the urine [34e36]. To reach the plasma
membrane B0AT1 requires coexpression of the ancillary protein col-
lectrin (TMEM27) in the kidney [37] and angiotensin converting enzyme
2 (ACE2) in the intestine [38]. Here we show that lack of the neutral
amino acid transporter B0AT1 improves glycaemic control through two
opposing signals: ﬁrst, an increased luminal load of amino acids in the
intestine and, second, a reduced systemic amino acid availability.
2. MATERIAL AND METHODS
2.1. Animal holding and high-fat diet
Mouse strain: Slc6a19 (/) mice were used as described before
[32]. Littermates were used as comparisons for all experiments. The
number of animals used in each experiment is provided in the ﬁgure
captions. Male mice were used for all physiological tests. Animal ex-
periments were approved by the animal experimentation ethics com-
mittee of the Australian National University (R.BSB.06.10). Two months
and six months old female mice were used for the high-fat diet
experiment. Four mice were housed per cage. High fat diet food was
custom designed and manufactured in dry, pelleted form by Specialty
Feeds (By energy 46% fat, 21.6% protein, 32.4 carbohydrates). Ani-
mals were kept on the diet for 4 months; body weight was measured
twice weekly.
2.2. Behavioural and metabolic phenotyping
Mice were individually housed for about 1wk prior to entering the
PhenoMaster Cage System (TSE Systems, Bad Homburg, Germany),MOLECULAR METABOLISM 4 (2015) 406e417 Crown Copyright  2015 Published by Elsevier GmbH. This is
www.molecularmetabolism.comwhich enables simultaneous determination of indirect calorimetry, 3D
activity, as well as food and water consumption. Mice were then
housed individually in the system for a total of 8d. Calculations of total,
lean- and body- mass adjusted oxygen consumption, carbon dioxide
production rates and respiratory exchange ratio were performed ac-
cording to established guidelines [39,40], averaged over the ﬁnal 3d of
housing, after a period of adaptation to the system. All mice were
maintained on a 12 h lightedark cycle at 22 C with unrestricted
access to food and water. Upon exiting the system, body composition
was determined by an Echo magnetic resonance imaging (ECHO-MRI)
body composition analyser (Echo Medical Systems, Houston, USA).
Faecal energy output was measured with the IKA C7000 calorimeter
(IKA, Staufen, Germany) from an aliquot of lyophilised, pulverised
faecal material collected over a 24 h period. Rectal temperature was
measured using a sensor (N856-1) and digital measurement device
(Almemo 2390-1; Ahlborn Mess-und Regelungstechnik GmbH, Ger-
many), and were made between ZT3-5 on two separate days in a
randomised order at standard laboratory temperature (i.e. 22e24 C).
2.3. GTT, IPITT, pyruvate challenge, tissue glucose uptake
GTT: Mice were fasted overnight (16 h) before the test. Glucose was
injected intraperitoneally (IPITT) or given by gavage (OGTT) (2 g/kg
body weight) and blood samples were taken from the tail vein before
and 30, 60, 90 and 120 min after the injection of glucose. Blood
glucose was determined with an Accu-chek Performa glucometer.
IPITT: To avoid hypoglycaemia, ITT were performed on randomly-fed
mice during daytime. The mice were injected intraperitoneally with
insulin (0.75 U/kg) in approx. 0.1 ml 0.9% NaCl. Blood samples were
taken from the tail vein before and 15, 30, 45, and 60 min after the
injection of insulin for the determination of blood glucose using an
Accu-chek Performa glucometer. Pyruvate challenge: Mice were fas-
ted for 4 h before the test. Pyruvate was injected IP (2 g/kg body
weight) and blood samples were taken before and 15, 30, 60 and
120 min after the injection of pyruvate. Blood glucose was measured
using Accu-Chek Performa glucometer.
Tissue glucose uptake: Mice were fasted for 16 h before intraperitoneal
injection of 12mCi/mouse [2-14C]deoxyglucose ([2-14C]DG) together
with glucose at a ﬁnal concentration of 2 g/kg. After 40 min, blood
glucose was measured using an Accu-Chek glucometer and a blood
sample taken to determine the speciﬁc activity of glucose in the blood.
Subsequently, mice were sacriﬁced and tissues were excised and
rinsed in ice-cold PBS/1 mM EDTA pH 7.4. Pieces of about 50 mg were
then snap-frozen in liquid nitrogen, weighed and homogenised in
0.5 ml 0.5% perchloric acid. After centrifugation in a table top
centrifuge 0.4 ml of the supernatant was removed and neutralised with
0.4 ml 0.3N KOH. One aliquot of the homogenate was used without
further treatment to measure the combined total activity of [2-14C]DG
and [2-14C]deoxyglucose-6P ([2-14C]DGP) (Beckman LS 5000TD,
Beckman Instruments, USA). A second aliquot of the homogenate was
treated with 0.15 ml 0.3M Ba(OH)2 and 0.15 ml 0.3M ZnSO4 to pre-
cipitate [2-14C]DGP and was then counted to yield [2-14C]DG radio-
activity. After adjusting for volume, the difference between the two
readings, was used as the amount of [2-14C]DGP. Speciﬁc activity was
calculated using blood [2-14C]DG volume activity in combination with
blood glucose concentration.
2.4. Metabolomic analysis
GC/MS: To detect short-chain fatty acids in faeces a 20 mg sample
was collected. The sample was mixed with 120 ml 0.2 M HCl, 300 mL
diethyl ether and 24 ml of 50 mg/ml heptanoic acid as internal stan-
dard. The sample was extracted by vortexing at room temperature foran open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 407
Original article10 min. After centrifugation in a table-top centrifuge for 5 min at
maximum speed, 50 ml of the organic layer was transferred to a new
tube. For derivatisation 40 ml of 20 mg/mL Methoxylamine-HCl in
pyridine was added and the sample incubated for 90 min at 30 C.
Subsequently 30 ml of N-tert-butyldimethylsilyl-N-methyltri-
ﬂuoroacetamide (MTBSTFA)/1% t-butyldimethylchlorosilane (TBDMCS)
was added and the sample was incubated at 80 C for another 30 min.
Derivatised metabolites were separated by gas chromatography using
a Varian FactorFour Capillary Column (VF-5ms 30 m  0.25 mm ID,
DF ¼ 0.25 mm þ 10 m EZ-Guard column) on an Agilent 7890A GC
system with the following parameters: Injection mode: Splitless; Inject
volume: 1 ml; Inlet temperature: 220 C; Carrier gas: Helium; Flow rate:
1 mL/min (7.6522psi); Temperature program: 50 C for 1 min, then
increasing by 5⁰C/min to 80 C, (holding for 3 min) followed by an
increase at 30 C/min to 275 C (holding for 5 min), resulting in a total
run time of 21.5 min.
Compounds were detected by an Agilent 5975C MS using the following
conditions: Ionisation: Electron impact (EI) @ 70 eV; MS acquisition
modes: full scan (50e700 m/z, 4 scans/min) for non-targeted me-
tabolites; selected ion monitoring (SIM) with ion dwell time of 40 ms for
quantiﬁcation of isovaleric acid; Transfer line temperature: 275 C; MS
source temperature: 250 C; Quadrupole temperature: 150 C; Solvent
delay: 10 min.
LC/MS/MS was used to quantify amino acid concentrations in plasma
and urine. Analysis, including sample preparation and derivatization was
performed using the EZ:faast kit (Phenomenex, Torrance, USA) ac-
cording to the user’s manual. For LC/MS/MS detection, an electrospray
ionisation-triple quadrupol mass spectrometer (Quantum Ultra, Thermo)
coupled to a liquid chromatography system (UltiMate3000, Dionex)
controlled by Xcalibur 2.0.7 software with Dionex Chrom MS link 6.80
was used. Chromatographic separation was achieved on an EZ:faast
AAA-MS column 250 2 mm (Phenomenex) at 35 C with a ﬂow rate of
250 mL/min; autosampler temperature was set to 10 C. A sample
volume of 1 ml was injected onto the column. Eluents consisted of 10mM
ammonium formate in water (A) and 10 mM ammonium formate in
methanol (B). Initial conditions (0 min) were 68% B, then linear gradient
was applied within 13 min to 83% B. The system returned to initial
conditions within 4 min and equilibrated for 7 min, resulting in a total run
time of 23 min per sample. The column ﬂow was directly converted into
the H-electrospray ionisation (HESI) source of the mass spectrometer,
which was operated in the positive ion mode. Capillary and vapouriser
temperatures were maintained at 350 C and 50 C, respectively.
Sheath gas and auxiliary gas were operated at 40 and 25 (pressure,
arbitrary units), no ion sweep gas was applied. Collision energy and tube
lens offset were adjusted accordingly to obtain the highest response for
the speciﬁc amino acid. Quantiﬁcation was performed via peak area
ratios applied to internal standards provided in the kit.
2.5. Metabolite and hormone analysis
Serum levels of insulin, triglycerides, cholesterol, ketone bodies, non-
esteriﬁed fatty acids (NEFAs), FGF-21, GLP-1, and GIP were deter-
mined using commercial assays as listed in Suppl. Table 1.
2.6. Western blots and antibodies
Frozen tissue samples were sectioned into 100 mg blocks and
homogenised in 1 mL of T-PER Tissue Protein Extraction Reagent
(Thermo Scientiﬁc). Protein was measured using the Bradford assay.
Protein samples were separated by SDS-PAGE and blotted onto
nitrocellulose membranes by electrophoretic transfer. After blocking
nonspeciﬁc binding sites, proteins were probed using antibody di-
lutions as listed in Suppl. Table 2. Proteins were detected by enhanced408 MOLECULAR METABOLISM 4 (2015) 406e417 Crown Copyright  2015 Published by Elseviechemiluminescence (ECL system, GE Healthcare). Blots were stripped
and re-probed to detect proteins in phosphorylated and non-
phosphorylated forms, and housekeeping genes as loading controls.
2.7. qRT-PCR
qRT-PCR was performed on a 7900HT Fast Real-Time PCR System
(Applied Biosystems) with SYBR green and Platinum DNA polymerase
(Invitrogen). The GAPDH gene was used as reference and relative
transcript levels of biosynthesis were calculated with the DDCt
method.
2.8. Statistical analysis
The number of mice used for each experiment is stated in the ﬁgure
legends. When comparing parametric data from two groups, the un-
paired t test was used. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
CellProﬁler software was used to analyse adipocyte area [41]. Sta-
tistical analyses of the calorimetric data were performed by SPSS, to
normalise for differences in bodyweight or body composition data were
analysed using ANCOVA, signiﬁcant difference assumed at P < 0.05.
3. RESULTS
3.1. Slc6a19 (/) mice have improved glycaemic control
As we have shown previously, Slc6a19 (/) mice lack the major
transport activity for neutral amino acids in both intestine and kidney.
This causes reduced amino acid absorption in the small intestine and
loss of amino acids through the urine ([32] and Figure S1). We also
obtained preliminary evidence that upon feeding after fasting, insulin
levels remained low although glucose levels were close to normal,
suggesting that insulin sensitivity might be enhanced in Slc6a19 (/)
mice [32]. To analyse glucose homoeostasis in more detail we per-
formed glucose tolerance tests and insulin tolerance tests. Glucose
tolerance was signiﬁcantly improved in 6 months old mice (AUC,
p < 0.0001), while the difference in 2 months old mice was non-
signiﬁcant (Figure 1A, B). Insulin sensitivity was improved in 2
months old mice (AUC, p ¼ 0.021), but did not reach signiﬁcance in 6
months old mice (Figure 1C, D). Surprisingly, very little insulin
secretion was observed during an IPGTT in 6 months old mice
(Figure 1E, note the different time scale, AUC p¼ 0.016). When placed
on a high-fat diet, 6 months old Slc6a19 (/) mice gained less
weight than aged-matched wildtype and heterozygous mice
(Figure 1F). Glucose tolerance was similar in both groups of mice after
4 months on a high-fat diet, but the insulin response was more sen-
sitive in Slc6a19 (/) mice (Figure S2).
Analysis of body composition on normal chow showed a slightly
reduced body weight and liver mass but more importantly a pro-
nounced reduction of abdominal white adipose tissue (Figure 2AeC).
Inguinal adipose tissue and brown adipose tissue were similar
(Figure 2D, E). When normalised relative to body weight, only the
abdominal white adipose tissue remained signiﬁcantly reduced in
Slc6a19 (/) mice. Moreover, average adipocyte area in Slc6a19
(/) mice was only half of that observed in wildtype mice (Figure 2F,
G). When expressed as % body weight, the total body fat was similar in
both groups: (þ/þ) Fat body mass 5.0 þ/ 1.1 g (18.6%), lean body
mass 20.3 þ/ 1.5 g (75.5%), n ¼ 11; (/); Fat body mass 3.7 þ/
 0.7 g (16.4%), lean body mass 17.5 þ/ 1.3 g (77.8%), n ¼ 8.
3.2. Slc6a19 (/) mice are not calorie restricted
A straight-forward explanation for the reduced weight gain on a high-fat
diet would invoke reduced nutrient uptake in the intestine. It is important
to note that reduced intestinal absorption will not explain the differencer GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1: Glucose tolerance and insulin tolerance of wildtype and Slc6a19(L/L) mice. (A, B) Glucose (2 g/kg) was injected IP to measure glucose tolerance in 2 and 6
months old fasting mice. (C, D) Insulin (0.75 U/kg) was injected IP to measure insulin tolerance in randomly fed mice. (E) IPGTT was performed as in (A, B) but insulin levels were
determined by ELISA. (F) Weight development on a high-fat diet. Statistical signiﬁcance for AUC comparison between groups is shown in panels AeE. Female mice were used for
the experiment in panel F; all other experiments were performed with male mice.observed in the glucose or insulin tolerance tests because of the injection
occurring into the peritoneum. The amount and energy content of the
faeces was the same in both animal groups (Figure 3AeC), suggesting
that amino acids get absorbed in the distal intestine and/or are converted
by the intestinal microﬂora into fermentation products, which are
absorbed by the colon. In support of this notion we observed increased
amounts of valeric and isovaleric acid, which are fermentation products
of branched-chain amino acids (Figure 3D). Fermentation products
arising from complex carbohydrates (propionic acid, butyric acid), by
contrast, were similar in both groups of mice. This indicates that amino
acids are transferred to more distal sites of the intestine where they are
fermented by the microﬂora. However, all nutrients are eventually
absorbed leaving the same amount of energy behind in the faces.
To determine the impact of reduced absorption and loss of neutral
amino acids in the urine we quantiﬁed amino acid levels in bloodMOLECULAR METABOLISM 4 (2015) 406e417 Crown Copyright  2015 Published by Elsevier GmbH. This is
www.molecularmetabolism.complasma and urine (Figure S1A, S1B). With the exception of 3-
methylhistidine, plasma amino acid levels were found to be very
similar, while urine neutral amino acid levels were highly elevated.
These amino acid levels are consistent with those observed in human
Hartnup disorder [42]. Two factors contributed to the stabilisation of
plasma neutral amino acid levels in Slc6a19 (/) mice. First, muscle
protein breakdown was reduced as indicated by lower plasma levels of
3-methylhistidine (Figure S1A), and, secondly, amino acids were
spared as energy substrates as indicated by lower levels of urea in
plasma and urine (Figure 3E, F). In summary, Slc6a19 (/) mice are
not calorie restricted, but use fewer amino acids for energy generation
and show reduced muscle protein turnover to keep plasma amino acid
levels at close to normal levels. Despite gaining less weight on a high-
fat diet, Slc6a19 (/) eat slightly more chow when normalised to
body mass (Figure 3G, H).an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 409
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Figure 2: Body composition of 6 months old wildtype and Slc6a19(L/L) mice. Animal and organ masses were determined by weighing: body mass (A), liver mass (B),
abdominal white adipose tissue (C), inguinal white adipose tissue, (D), and brown adipose tissue (E). Organ mass is displayed as % of body mass. (F) H&E staining of aWAT and
iWAT adipocytes, scale bar is 100 mm. (G) Statistical analysis of adipocyte area in abdominal and inguinal white adipose tissue. Male mice were used for the experiments.
Original article3.3. Slc6a19 (/) mice have increased energy expenditure
As an alternative, increased energy expenditure may explain the
reduced weight gain on a high-fat diet. To investigate this possibility,
we performed indirect calorimetry and analysed expression of
uncoupling protein in brown adipose tissue. When normalised to lean
body weight, oxygen consumption and CO2 production was elevated in
Slc6a19 (/)mice, but the respiratory exchange ratio (RER) was very
similar (Figure 4A). At a ﬁxed hypothetical lean body weight of 19.1 g
the data analysis predicted a VO2 of 104 2 ml/h and 96 2 ml/h for
Slc6a19 (/) and wildtype, respectively (p¼ 0.033) (Figure 4B). This
demonstrates increased energy expenditure in the Slc6a19 (/)
mice independent of the known body-weight effect on energy con-
sumption [43]. However, there was no increase of BAT volume in
Slc6a19 (/) mice, and no increase of UCP1 expression in BAT
(Figures 2 and 4C). Consistent with these data, BAT glucose con-
sumption (Figure 4D) and body temperature (Figure 4E) was the same
in both groups of mice. To explain the increased energy expenditure
we wondered whether browning of white subcutaneous adipose tissue
might occur in Slc6a19 (/) mice. In support of this notion we could
detect signiﬁcant expression of UCP-1 in inguinal WAT in Slc6a19
(/) mice, but not in wildtype littermates (Figure 4C).
3.4. Slc6a19 (/) mice show elevated levels of FGF21
It has been reported that FGF21 causes browning of white adipose
tissue [44,45]. In agreement with this notion, ad libitum fed 6 months410 MOLECULAR METABOLISM 4 (2015) 406e417 Crown Copyright  2015 Published by Elsevieold Slc6a19 (/) mice had signiﬁcantly elevated levels of FGF21
(Figure 5A), which were also observed at a slightly lower level in 2
months old mice (Figure 5B). In fasting animals, which generally have
high FGF21 levels, only a small increase was observed (Figure S3A).
Blood metabolites were also found to be consistent with elevated levels
of FGF21 (Figure 5CeH) [44]. Ketone bodies and creatinine were
signiﬁcantly increased, blood glucose was normal, while serum tri-
glyceride, cholesterol and non-esteriﬁed fatty acid levels were
reduced. Under fasting conditions only small differences of metabolite
levels were observed (Figure S3BeD). Consistent with this metabolite
proﬁle we found increased expression of fgf21 in the liver (Figure 5I).
The fgf21 gene is regulated by the heteromeric transcription factor
PPARa/RXR in liver [46]. However, in microarray studies we did not ﬁnd
increased expression of key PPARa target genes such as acyl-CoA
oxidase (ACOX1) or carnitine palmitoyl transferase 1a (CPT1a) [47],
which was conﬁrmed by real time PCR (Figure 5I). Alternatively, amino
acid starvation can trigger transcription of fgf21 through an amino acid
response element in liver [17,18]. Consistent with reduced amino acid
ﬂux to the liver, we found elevated levels p-eIF2a in liver, similar to
observations in the intestine reported by us previously (Figure 5K) [32].
3.5. Slc6a19 (/) mice have reduced mTOR signalling
FGF21 has been proposed to increase glucose removal by a variety of
mechanisms [44,48,49], but glucose tolerance and insulin sensitivity
could also be improved due to reduced amino acid availability. Elevatedr GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 3: Energy consumption in wildtype and Slc6a19(L/L) mice. Faecal dry mass (A), faecal energy (B) and faecal energy output (C) was measured. (D) The amount of
short-chain fatty acids in faecal samples was determined by GCeMS. Urea content was determined in randomly fed animals in urine (E) and serum (F). A Phenomaster system was
used to determine daily food intake (G), and food intake per body mass (H). Male mice were used for the experiments.levels of serum amino acids will increase signalling through the mTOR
pathway including p70S6 kinase. Activation of the mTOR pathway
results in phosphorylation of several residues of the IRS-1 protein,
which can cause insulin resistance [50,51]. Although the direct
phosphorylation sites targeted by mTOR and p70S6 kinase are
disputed [52], inhibition of mTOR by rapamycin signiﬁcantly reducesMOLECULAR METABOLISM 4 (2015) 406e417 Crown Copyright  2015 Published by Elsevier GmbH. This is
www.molecularmetabolism.comphosphorylation of IRS-1 residues S302, S307 and S318 [51]. Phos-
phorylation of these sites is associated with insulin resistance and also
results in IRS-1 degradation. In our experiments we used ribosomal
protein S6 phosphorylation as a readout for mTOR and p70S6 kinase
activity and monitored insulin receptor sensitivity by detection of IRS-
1(pS307) and protein kinase Akt(pS473) phosphorylation. Consistentan open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 411
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Original articlewith lower amino acid availability, mTOR signalling was found to be
reduced in muscle, adipose and liver from ad libitum fed animals
(Figure 6A). No difference was observed in fasting animals
(Figure S3E). Levels of IRS-1 were higher in the liver of Slc6a19 (/)
mice, while adipose and muscle showed little difference (Figure 6B). If
anything, levels of IRS-1(pS307) were increased in muscle and adi-
pose tissue (Figure 6B). Levels of protein kinase Akt were similar in
liver, muscle and adipose tissue in both groups of mice. pAkt(S473)
was not detectable in unstimulated liver and muscle, but was easily
detected in adipose tissue of Slc6a19 (/) mice (Figure 6C). After
stimulation with insulin, similar levels of pAKT were detected in both
groups of mice in all three tissues (Figure 6D).
3.6. Slc6a19 (/) mice show reduced hepatic glucose output
and liver triglycerides
Hepatic insulin resistance is correlated with enhanced glucose output
via gluconeogenesis and elevated liver triglycerides. To investigate the
effect of B0AT1 deﬁciency on liver gluconeogenesis we used a pyruvate
challenge. The data show a slightly reduced glucose output after IP
injection of pyruvate (Figure 7A), with borderline signiﬁcance when the
starting glucose concentration was normalised (AUC normalised,
p ¼ 0.07). Moreover, we also found reduced levels of triglycerides
(Figure 7B), which may result from conversion of liver fat into ketone
bodies.
3.7. Slc6a19 (/) mice show increased levels of GLP-1
As shown above, UCP-1 was upregulated in inguinal white adipose
tissue, which was accompanied by a signiﬁcant increase in glucose
consumption (Figure 7C). To identify other organs which contributed to412 MOLECULAR METABOLISM 4 (2015) 406e417 Crown Copyright  2015 Published by Elsevieglucose removal, we injected radiolabelled glucose during an IPGTT
and measured its distribution among organs after 1 h (Figure 7D). No
notable difference was observed in insulin-sensitive muscle and
abdominal white adipose tissue. Glucose consumption in BAT
(Figure 4D), intestine, brain and lung was also unaltered. Gluconeo-
genesis in liver and kidney may confound the absolute values in these
tissues, but overall no difference was observed. By contrast, glucose
consumption by the heart was signiﬁcantly increased in Slc6a19
(/) mice. It has been reported that GLP-1 increases glucose con-
sumption in heart [53,54]. Since amino acids prevail in the lumen of
the intestine for longer periods and are found in further distal sections
than in wildtype mice (Figure 3D), we hypothesised that incretin
secretion could be increased. In agreement with this notion we found
that GLP-1 and GIP levels were signiﬁcantly elevated in Slc6a19 (/)
mice after oral food consumption (Figure 7E,F). Surprisingly, Slc6a19
(/) have lower insulin secretion than wildtype mice even after
glucose gavage (Figure 7G), suggesting that the incretin effect is
subdued. To investigate whether insulin secretion was principally
defective, we doubled the amount of glucose injected during an IPGTT
(4 g/kg). In this experiment the blood glucose response in Slc6a19
(/) mice became similar to that of the wildtype at 2 g/kg glucose
injection (Figure 7H) and insulin secretion was observed (Figure 7I).
Thus insulin secretion is not defective, but the threshold appears to be
altered. We wondered whether B0AT1 could directly inﬂuence amino
acid-induced insulin release as its mRNA has been detected in small
amounts in pancreas [32]. However, several attempts to identify B0AT1
protein expression in the pancreas using antibodies previously used to
detect B0AT1 protein in kidney and intestine [32] failed to provide
evidence for expression in b-cells (data not shown).r GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 5: Metabolite and gene expression proﬁles in wildtype and Slc6a19(L/L) mice. Serum content of FGF-21 was measured by ELISA in 6 months old animals (A) and
2 month old animals (B). Metabolite levels were determined using enzymatic tests (CeH). Quantitative PCR was used to determine liver expression levels of ﬁbroblast growth factor
21 (FGF-21), uncoupling protein 1 (UCP-1), fatty acid acyl oxidase-1 (ACOX-1), carnitine palmitoyl transferase 1 (CPT-1A), hydroxymethylglutaryl-CoA synthase 2 (HMGCS2),
lipoprotein lipase (LPL), branched-chain amino acid transferase (BCAT1) (I). Amino acid depletion in liver was determined by immunodetection of initiation factor 2a and its
phosphorylated form (K). Male mice were used for the experiments.In summary, our results suggest that the metabolic phenotype of
Slc6a19 (/) mice can be explained by the heart acting as a
glucose sink, most likely caused by increased GLP-1 secretion from
the intestine. Due to the reduced ﬂux of amino acids to the liver,
FGF21 is produced, which causes up-regulation of UCP-1 in subcu-
taneous fat. Both mechanisms will remove glucose without requiring
insulin. FGF21 in addition causes break-down of fat to produce ke-
tone bodies.
4. DISCUSSION
Lack of neutral amino absorption in the intestine caused by B0AT1
deﬁciency results in two opposing signals that contribute to the
metabolic phenotype of Slc6a19 nullizygous mice. First, reduced up-
take in the intestine causes accumulation of amino acids in the lumenMOLECULAR METABOLISM 4 (2015) 406e417 Crown Copyright  2015 Published by Elsevier GmbH. This is
www.molecularmetabolism.comand occurrence of free amino acids in more distal parts of the intestine.
This phenomenon has also been observed in ACE2-deﬁcient mice,
which lack expression of B0AT1 in the intestine because of the missing
trafﬁcking protein that brings B0AT1 to the cell surface [55]. Further
indication of distal occurrence of amino acids is the production of
short-chain fatty acids resulting from fermentation by the intestinal
microﬂora. Overall the high luminal amino acid concentration sends a
“full” signal to the body, particularly through the secretion of GLP-1
and GIP. Both peptide hormones are secreted by speciﬁc enter-
oendocrine cells, which sense luminal amino acid content as a signal
for secretion [56,57]. The second signal is generated by the liver. As
evidenced by reduced mTOR signalling and phosphorylation of eIF2a,
lack of B0AT1 in the intestine reduces the inﬂux of amino acids through
the portal vein to the liver after a meal. This amino acid starvation
response is known to increase fgf21 transcription through amino acidan open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 413
Figure 6: Amino acid and insulin signalling in ad libitum fed wildtype and Slc6a19(L/L) mice. (A) Signalling through the mTOR pathway was measured by analysing
unphosphorylated (S6) and phosphorylated (P-S6) ribosomal protein S6 in liver, muscle and white adipose tissue. (B) Insulin signalling and insulin sensitivity was measured by
analysing total and phosphorylated IRS-1 (P307-IRS-1) in liver, muscle and adipose tissue. (C) Detection of AKT and P473-AKT in liver, muscle and adipose tissue. (D) Detection of
AKT and P473-AKT in liver, muscle and adipose tissue 30 min after 0.75 U/kg insulin injection. Male mice were used for the experiments.
Original articleresponse elements in the promoter region of the gene [17,18]. Sur-
prisingly, the difference of FGF21 serum levels (27-fold) was much
higher than the change of mRNA expression in liver (5-fold). These
data were conﬁrmed in microarray experiments showing a 6-fold in-
crease in liver, while FGF21 expression was below threshold in adipose
tissue and muscle (data not shown). Western blot of pancreas tissue
also revealed no difference in FGF21 levels between the two groups of
mice (data not shown). These results point to a possible increase of the
biological half-life in Slc6a19 (/) mice, which remains to be
determined. The phenotype of Slc6a19 (/) mice appears to be a
combination of GLP-1 and FGF-21 induced signals. Reduced hepatic
glucose output, increased oxidation of fatty acids and ketogenesis are
metabolic programs elicited by FGF21 through the FGF21/b-klotho
receptor [20]. Moreover, reduced insulin levels have also been re-
ported after injection of FGF21 [58]. The response to FGF21 secretion
in Slc6a19 (/) mice is similar to that in other model systems
[44,59]. In view of adipose tissue being the major target of FGF21
action [21], it is tempting to speculate that FGF21 may be involved in
phosphorylation of AKT in non-insulin treated adipose tissue of
Slc6a19 (/) mice. It has furthermore been shown that FGF21 in-
creases adiponectin expression and excretion in adipose tissue and
that this could be the basis for many of its metabolic effects [58]. In
microarrays we could not detect enhanced expression of adiponectin in
abdominal adipose tissue, but it remains to be shown whether it is up-
regulated in inguinal WAT.414 MOLECULAR METABOLISM 4 (2015) 406e417 Crown Copyright  2015 Published by ElsevieIncreased glucose consumption by the heart is thought to arise through
GLP-1 [53]. Together both signals result in a phenotype that is highly
desirable in the context of managing metabolic syndrome and
diabetes.
The increased glucose consumption by the heart (1 mmol/g*min) makes
a signiﬁcant contribution to the IPGTT. The average weight of a mouse
heart is 150 mg resulting in an additional glucose consumption of
150 nmol/min. In the standard IPGTT (Figure 1) we observed a difference
between wildtype and Slc6a19 (/) mice of about 8 mM/30 min.
Assuming a blood volume of 1.5 ml, this amounts to 400 nmol glucose/
min, explaining about 40% of the time course. The reminder most likely
can be attributed to glucose consumption by subcutaneous WAT and
reduced glucose output by the liver. Over time adipose tissue and tri-
glycerides in liver are reduced due to the conversion into ketone bodies.
Why b-cells release so little insulin despite increased secretion of
insulinotropic peptide hormones GLP-1 and GIP remains to be deter-
mined. In part, it is caused by largely insulin-independent glucose
removal by the heart and inguinal adipose tissue. As a result blood,
glucose levels rise more slowly, thereby reducing insulin secretion.
However, at a plasma glucose concentration of >10 mM, as observed
during the IPGTT, signiﬁcant insulin secretion is expected. A similar
lack of response has also been observed in ACE2 (/) mice, which
lack B0AT1 in the intestine [60,61]. In terms of managing diabetes and
metabolic syndrome, this reduced response may offer additional
beneﬁts, such as protection of b-cells against endoplasmic reticulumr GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 7: Regulation of glucose metabolism in wildtype and Slc6a19(L/L) mice. (A) Pyruvate (2 g/kg) was injected IP to measure hepatic glucose output in 6 months old
fasting mice; (B) liver content of triglycerides. (C, D) Glucose (2 mg/kg) mixed with [14C]deoxyglucose was injected IP to measure glucose uptake in a variety of tissues after 40 min.
Serum levels of GLP-1 (E) and GIP (F) were determined before and 60 min after oral food consumption. Insulin levels were measured before and 60 min after glucose gavage (G).
Blood glucose (H) and insulin levels (I) were measured after IP injection of glucose (2 g and 4 g/kg) into Slc6a19 (/) mice. Male mice were used for the experiments.stress [62]. In addition, it establishes amino acid absorption as a
signiﬁcant modulator of fuel-induced insulin secretion. In humans and
rats GLP-1 and GIP send satiation signals to the brain, which we do not
seem to observe, for Slc6a19 (/) mice appear to be slightly hy-
perphagic, when normalised to body weight.
The lack of B0AT1 in the kidney is likely to contribute to the observed
phenotype, as suggested by a similar metabolic phenotype observed in
collectrin deﬁcient animals [63], which lack B0AT1 only in the kidney.
ACE2 (/) mice, which lack B0AT1 in the intestine, have a distinct
phenotype caused by increased levels of angiotensin II [61], but share
reduced insulin secretion.
Despite the loss of amino acids in the urine and reduced uptake in the
intestine, plasma amino acid levels in fasting animals remained largely
normal. Two factors contributed to this surprising result. First, amino
acids were spared as fuels as demonstrated by the reduced urea
concentration in blood plasma and urine. Secondly, muscle protein
turnover and degradation was reduced as indicated by lower 3-
methylhistidine concentrations in blood plasma. This result is
consistent with the observation that increased plasma concentrationsMOLECULAR METABOLISM 4 (2015) 406e417 Crown Copyright  2015 Published by Elsevier GmbH. This is
www.molecularmetabolism.comof branched-chain amino acids cause increased protein turnover and
energy consumption [64].
5. CONCLUSIONS
Slc6a19 (/) mice demonstrate a signiﬁcant role of neutral amino
acids in the regulation of fuel metabolism, which has only partially
appreciated previously. Curtailing amino acid absorption in the intes-
tine causes increased production of GLP-1 by the intestine and in-
creases FGF-21 production by the liver. These results establish a novel
target to treat type 2 diabetes and its associated comorbidities.
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